


Your biosimilar, your journey

For biosimilar developers, stars are now within reach. With blockbuster drug patents for more than \$200 billion in annual revenue set to expire by 2030 (1), there's a world of opportunities on the horizon. To be successful, developers must carefully consider their market strategy and manufacturing goals.

Are you ready for lift off?



All systems go: Complete your pre-launch checklist

Target the right biosimilar

It is important to weigh your timing, target market, and team's expertise, including regulatory, against what patents are expiring.

Choose the best path forward

Implementing the setup that is right for your needs—single-use or stainless steel, permanent or modular—will offer the best return on your investment.

Map out ideal timeline

Whether you want to be first, second, or third to market, timing matters. Your market entry point will impact late-stage production and regulatory decisions.

Optimize efficiencies to save time and money

Consumables selection


Consumables make up the majority of recurring expenses. However, with help choosing the right consumables, they'll last longer, saving you money without reducing quality.

Mechanistic modeling

Mechanistic modeling allows you to further reduce risk, time, and costs, from your design of experiment (DoE) phase to process development and manufacturing.

Get digital

Choosing the right automation and digital solutions—no matter where you are in your digital transformation—can save trial and error, helping you get it right the first time.



Stay on course with expertise by your side

Process development (PD) services

Outsourcing PD services can help you develop and optimize your process, from project management to media development and tech transfer—speeding your time to market.

Upskill your team

Seek out third-party training resources that incorporate a blended learning approach to get to get staff up and running when you need them.

Meet regulatory guidelines

Every market has its own set of regulations, so checking your regulatory steps is key to a successful approval. We can help you with regulatory considerations in the United States and European Union.

Lift off with Cytiva as your helping hand in your biosimilar manufacturing.

Contact us today



References

1. Philippidis A. As patent cliff looms for biopharma giants, smaller biotechs face cash crunch. Genetic Engineering and Biotechnology News. <https://www.genengnews.com/topics/bioprocessing/as-patent-cliff-looms-for-biopharma-giants-smaller-biotechs-face-cash-crunch/> Published June 21, 2023. Accessed August 29, 2025.

www.cytiva.com

Cytiva and the Drop logo are trademarks of Life Sciences IP Holdings Corporation or an affiliate doing business as Cytiva. Any other trademarks are the property of their respective owners.

The Danaher trademark is a proprietary mark of Danaher Corporation.

© 2025 Cytiva

For local office contact information, visit cytiva.com/contact

CY51333-16Sep25-IG